Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2201 participants.
Also called NCT03560310
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,201 participants
- Registry
-
NCT03560310
-
- Other papers using this trial's data
- Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Denmark, Finland, Iceland, Norway, Sweden
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03560310. Randomized; no masking; primary purpose treatment. Start 2018-06-29 (actual); primary completion 2025-03-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
- Acronym
- TACSI
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Ticagrelor 90mg twice daily and ASA 75-100 mg daily
- Intervention (Drug)
- ASA 75-160 mg daily
- Lead sponsor
- Vastra Gotaland Region
- Collaborator
- Gothia Forum - Center for Clinical Trial
- Collaborator
- Göteborg University
Record details
- Record id
cardio:ct-nct03560310- Content hash
4341c5b2e5dc0b62359593f0926cb1559ff51708265d43dfc5f49bc80e4e2f74